Drug Discovery Ai Pharmaceutical Research News Top Stories October 2026 — Latest Developments and Key Updates

Pharma AI – The Q&A notes that artificial intelligence now handles the entire drug discovery phase, identifying promising compounds without human input, and includes comments from leaders at Pfizer and Novartis who say the AI platform integrates genomic data.

Drug Discovery – Researchers claim AI models can screen millions of molecules in days, cutting early‑stage costs by an estimated 70 percent, but the analysis relies on existing databases rather than new lab work, allowing scientists to shift focus to safety testing.

Execution Process – Despite advances, the article stresses that moving from identified candidates to clinical trials still requires manual laboratory work, regulatory paperwork, and human judgment, keeping execution largely manual and adding months to timelines and increasing overhead.

Industry Outlook – Analysts quoted say the split between automated discovery and manual execution will shape investment, with pharma firms planning to pair AI tools with traditional teams to bridge the gap, and they expect a 15 percent rise in AI